Brent T. Mclaurin

Brent T. Mclaurin

Cardiology

100 Gavotte Lane
Anderson, SC 29621

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy.

The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy.

Journal: Journal of the Society for Cardiovascular Angiography & Interventions

Published: December 22, 2022

Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III.

Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III.

Journal: Journal of the Society for Cardiovascular Angiography & Interventions

Published: August 04, 2022

Patients With Diabetes at High Bleeding Risk With 1-Month Dual Antiplatelet Therapy: Onyx ONE Clear Results.

Patients With Diabetes at High Bleeding Risk With 1-Month Dual Antiplatelet Therapy: Onyx ONE Clear Results.

Journal: Journal of the Society for Cardiovascular Angiography & Interventions

Published: May 10, 2022

Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus.

Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus.

Journal: Journal of the Society for Cardiovascular Angiography & Interventions

Published: December 15, 2021

Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy.

Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy.

Journal: Journal of the Society for Cardiovascular Angiography & Interventions

Published: October 12, 2021

Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial.

Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial.

Journal: Circulation

Published: April 06, 2021

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.

Journal: Circulation. Cardiovascular interventions

Published: November 10, 2020

Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study.

Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study.

Journal: Circulation. Cardiovascular interventions

Published: April 14, 2020

First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.

First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.

Journal: JACC. Cardiovascular interventions

Published: April 10, 2017

Bleeding risk factors affecting warfarin therapy in the elderly with atrial fibrillation.

Bleeding risk factors affecting warfarin therapy in the elderly with atrial fibrillation.

Journal: Dimensions of critical care nursing : DCCN

Published: February 06, 2014

Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Journal: The New England journal of medicine

Published: March 12, 2013

Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.

Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.

Journal: Coronary artery disease

Published: February 28, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026